ePatient / Health 2.0 - A Key Factor for New and Innovative Business Models for the Life Sciences Industry

17 November 2011, Düsseldorf, Germany.
InterComponentWare AG (ICW), an internationally focused company specializing in technology solutions for the healthcare market, invites to a podium discussion during the Medica Media Forums. Follow the newest discussions at Medica 2011 in Düsseldorf and take advantage of the opportunity to discuss with subject matter experts. ICW representatives are looking forward to meeting you at 3:00 pm on Thursday, 17th November 2011 at the MEDICA Media Forum in Hall 15 (Stand A11).

Today's patients are well informed and capable of making their own decisions when it comes to healthcare. When making their decisions about health products and services they utilize both real-world channels and electronic channels of the internet. Increasingly, the "ePatient" is becoming a factor in the "Health 2.0 ecosystem".

ICW develops innovative solutions for the healthcare system under the slogan "connect. manage. personalize." Get a new perspective and discover how solutions from ICW can help you to network disparate actors, support care-critical processes, and create options for modern interaction to engage the patient in the treatment process.

Take time to visit ICW at MEDICA in Hall 15, Stand F35 to get an interesting look at modern eHealth solutions.

Arrange a personal appointment here: http://www.icw-global.com/en/press-events/medica-appointment.html, or send an email to Mr. Silvio Frey This email address is being protected from spambots. You need JavaScript enabled to view it.
Upon request ICW representatives will also gladly send complementary admission tickets or informational material.

About ICW
ICW is an international healthcare technology provider. Our robust software and techniologies help to network the various actors, optimize care and engage patients in the treatment process. Our products are based on the ICW eHealth Platform, a suite of powerful technology components that support the quick assembly of eHealth solutions and the flexible implementation of integration scenarios. Together with our partners, our goal is to enable interoperability among healthcare stakeholders to harvest potentials and realize innovative forms of cooperation and collaboration. For more information go to www.icw-global.com.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Researchers call for worldwide biosurveillance net…

The emergence of COVID-19 is a powerful reminder of how unchecked wildlife trade can lead to the spillover spread of viruses between wildlife and humans. Understanding th...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

New study supports remdesivir as COVID-19 treatmen…

The news about remdesivir, the investigational anti-viral drug that has shown early promise in the fight against COVID-19, keeps getting better. This week researchers at ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies in the battle against COVI…

An important line of defence in the fight against the new corona virus SARS-CoV-2 is the formation of neutralising antibodies. These can eliminate the intruders and have ...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Sanofi and Regeneron provide update on Kevzara® (s…

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical v...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...